Search Results - "MIRZAEV, K. B."

CYP2C1917 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban by Sychev, D A, Baturina, O A, Mirzaev, K B, Rytkin, E, Ivashchenko, D V, Andreev, D A, Ryzhikova, K A, Grishina, E A, Bochkov, P O, Shevchenko, R V

“…The aim of this study is to assess the influence of gene and polymorphisms on clopidogrel antiplatelet activity, rivaroxaban concentration equilibrium, and…”
Get full text

Comparative clinical and economic evaluation of pharmacogenetic testing application for dabigatran in patients with atrial fibrillation by Abdullaev, Sh P, Mirzaev, K B, Sychev, D A

“…Aim. To evaluate the clinical and economic feasibility of pharmacogenetic testing (PGT) for dabigataran etexilate administration in the treatment of atrial…”
Get full text

Micro-RNA as a new biomarker of activity of the cytochrome system P-450: significance for predicting the antiplatelet action of P2Y12 receptor inhibitors by Rytkin, E I, Mirzaev, K B, Bure, I V, Sychev, D A

“…MicroRNAs are short non - coding RNAs that correlate with the levels of platelet activation which can be utilized as a biomarker when guiding P2Y12 inhibitors…”
Get full text

Analysis of carrying clinically significant allelic variants of TPMT and DPYD genes associated with the response to drug therapy in cancer practice among 9 ethnic groups of the Russian Federation by Mirzaev, K B, Fedorinov, D S, Akmalova, K A, Abdullaev, S P, Kachanova, A A, Sozaeva, Z A, Grishina, E A, Shuev, G N, Kitaeva, E Y, Shprakh, V V, Suleymanov, S S, Bolieva, L Z, Sozaeva, M S, Zhuchkova, S M, Gimaldinova, N E, Sidukova, E E, Burashnikova, I S, Shikaleva, A A, Zabudskaya, K G, Sychev, D A

“…To study the peculiarities of carrying clinically significant allelic variants of TPMT and DPYD genes associated with the response to drug therapy in cancer…”
Get full text

Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention by Mirzaev, K. B., Sychev, D. A.

“…The use of hydroxychloroquine for COVID-19 treatment and prevention should be restricted in both out- and inpatient settings due to the lack of evidence for…”
Get full text

Patients’ Pharmacogenetic Characteristics and the Risk of Adverse Reactions to Non-steroidal Anti-inflammatory Drugs: Case Reports by Zhiryakova, A. S., Denisenko, N. P., Kryukov, A. V., Akmalova, K. A., Tuchkova, S. N., Mirzaev, K. B., Sychev, D. A.

“…INTRODUCTION.  The variability in patient response to non-steroidal anti-inflammatory drugs (NSAIDs) may be due to genetic polymorphisms…”
Get full text

Pharmacogenetic Markers of Favipiravir Safety in COVID-19 Treatment by Temirbulatov, I. I., Kryukov, A. V., Mirzaev, K. B., Denisenko, N. P., Abdullaev, S. P., Petrova, A. V., Tkach, E. P., Shipacheva, A. V., Sychev, D. A.

“…The aim of the study was to evaluate the associations of different variants of AOX1 and CYP1A2 genes with safety parameters of favipiravir therapy in patients…”
Get full text

Genogeographic technologies of a population biobank as a tool for assessing selection effects (using the example of pharmacogenetic biomarkers of cardiovascular diseases) by Balanovskaya, E. V., Gorin, I. O., Ponomarev, G. Yu, Pylev, V. Yu, Belov, R. O., Pocheshkhova, E. A., Abdullaev, Sh. P., Mirzaev, K. B., Sychev, D. A.

“…Significant differences between the gene pools of Russian peoples require the development of ethno- regional adapted pharmacogenetic tests and the…”
Get full text

Possibility for the use of bromhexine to prevent infection with SARS-CoV-2 by Zagorodnikova, K. A., Mirzaev, K. B., Sychev, D. A.

“…The routine use of bromhexine to prevent infection SARS-CoV-2 is not recommended. The use of bromhexine is possible in clinical trials…”
Get full text

Current and future use of remdesivir in patients with COVID-19 by Tsvetov, V. M., Mirzaev, K. B., Sychev, D. A.

“…There are prerequisites for the use of remdesivir against SARS-CoV-2 in stationary conditions. Remdesivir is not registered in the Russian Federation. The…”
Get full text

Dexamethasone use in patients with COVID-19 by Otdelenov, V. A., Mirzaev, K. B., Sychev, D. A.

“…Dexamethasone may be used for mortality reduction in patients with severe COVID-19…”
Get full text

Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab by Mirzaev, K. B., Kiselev, Yu. Yu, Sychev, D. A.

“…No robust evidence proving clinical effectiveness of methylprednisolone in acute respiratory distress-syndrome in COVID-19, including combined use with…”
Get full text

Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19 by Otdelenov, V. A., Mirzaev, K. B., Sychev, D. A.

“…Hospitalized patients with COVID-19 who have not previously received DOAK by it is not advisable to prescribe POAC for the prevention of thrombosis in patients…”
Get full text

Can inhalations of hyaluronidase be used in acute respiratory distress-syndrome in patients with COVID-19? by Kiselev, Yu. Yu, Mirzaev, K. B., Sychev, D. A.

“…Hyaluronidase is currently not included into Russian or foreign guidelines on the treatment of acute respiratory distress-syndrome in patients with COVID-19,…”
Get full text

Could canakinumab be used for COVID-19? by Otdelenov, V. A., Mirzaev, K. B., Sychev, D. A.

“…Use of canakinumab in patients with COVID-19 is currently lacking proper evidence base, and should not be recommended outside of clinical trials…”
Get full text

Is it possible to use riamilovir to prevent infection and treat COVID-19? by Tsvetov, V. M., Mirzaev, K. B., Sychev, D. A.

“…Routine clinical use of riamilovir in COVID-19 is not recommended. The use of riamilovir is possible in clinical trials…”
Get full text

Features of drug-drug interactions rivaroxaban and calcium channel blockers depending on the ABCB1 genotype (rs1045642 and rs4148738) in patients 80 years of age and older with non-valvular atrial fibrillation by Sychev, D. A., Mirzaev, K. B., Cherniaeva, M. S., Shakhgildyan, N. V., Abdullaev, Sh. P., Denisenko, N. P., Sozaeva, Zh. A., Kachanova, A. A., Shastina, V. R., Gorbatenkova, S. V.

“…Background . The use of P-glycoprotein (P-gp) inhibitors and carriage of certain ABCB1 polymorphisms can lead to increased concentrations of rivaroxaban and…”
Get full text

The rs11385942 and rs657152 variants are not associated with COVID-19 severity and outcomes in patients treated with favipiravir and remdesivir by Abdullaev, Sh. P., Denisenko, N. P., Temirbulatov, I. I., Kachanova, A. A., Tuchkova, S. N., Mikhaylenko, E. V., Kryukov, A. V., Valiev, T. T., Mirzaev, K. B., Sychev, D. A.

“…Background . There is a mounting evidence in the scientific literature that susceptibility to SARS-CoV-2 infection could vary. The severity of COVID-19…”
Get full text

Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease by Shatalova, N. A., Sychev, D. A., Mirzaev, K. B., Kochetkov, A. I., Ebzeeva, E. Yu, Dashabylova, V. B., Bochkov, P. O., Tuchkova, S. N., Glagolev, S. V.

“…Aim . To study the possible relationship between polymorphic variants of ABCB1 ( rs2032582, rs1045642, rs1128503 ), CYP3A5 ( rs776746 ), CYP3A4 ( rs35599367 )…”
Get full text

The Effect of Carriage of CYP3A53 and CYP3A422 Polymorphic Variants on the Safety of Remdesivir Therapy in Patients with COVID-19 by TEMIRBULATOV, I. I., KRYUKOV, A. V., MIRZAEV, K. B., DENISENKO, N. P., ABDULLAEV, S. P., ZHIRYAKOVA, A. S., SHEVCHUK, Y. V., VECHORKO, V. I., AVERKOV, O. V., SYCHEV, D. A.

“…The aim of the study was to assess the association of polymorphic variants CYP3A5*3 6986 A>G rs776746 and CYP3A4*22 rs35599367 C>T with the safety parameters…”
Get full text